Final Thoughts on Management of Nasal Polyposis

Anju Peters, MD: In closing, thank you to all of you for this rich and informative discussion. You know, my final thought on this is, we talked about nasal polyposis, which is 20% of CRS. But hopefully, in a few years, we'll be talking about CRS without nasal polyps, which is 80% of CRS. And before we completely ended, I'd like to get final thoughts from each of you. Let's start with you, Naveen.

Naveen Bhandarkar, MD: It's exciting to see what's on the horizon, how we can improve our care. I like what Drew mentioned about the multidisciplinary collaboration. It makes you feel any better, we don't have allergists in our office here, but I agree with you. I think long term, I think that would be a really good treatment model. And above all, I really enjoyed being on the panel today. Thank you, Dr Peters, for including me, and I appreciate all the discussion. And I too, learn something today. So again, thank you.

Anju Peters, MD: Thank you, and hey, if it makes you feel any better, we do have a joint clinic and we agree more people should do it. It doesn't have to be brick and mortar if you communicate, it works fine. We do both. Any concluding comments from you, Drew?

Andrew White, MD: You know, I'm always struck at the very beginning, you talked about the prevalence, you know, in 6 to 12% of people. And you know, when you stated a different way that 1 in 8 people have CRS, it's crazy. And I'm always, you know, frustrated when I see a patient who clearly has been suffering for a long time and they show up and its sort of obvious right from the get-go what's going on. And they've just sort of been flying under the radar for some time of years. And I'm really happy to be part of anything that's an increased awareness and get other physicians just to think about looking for this condition.

Anju Peters, MD: How about you, Dareen? Final comment?

Dareen Siri, MD, FAAAAI, FACAAI: I thank you so much for organizing this multidisciplinary discussion. And certainly, regarding some of the patients, since you pointedly asked me about, you know, the vulnerable patients, elderly patients, things like that. You know, it's interesting to think about because we're seeing a lot more of adult-onset atopic dermatitis, adult-onset asthma. And certainly, we know that from several publications that patients over the age of 65, it's like the six most burdensome disease, which is chronic rhinosinusitis. It's not something that is only a disease of the young effect. It's probably more prevalent in the older. And as the population ages, as we think about their vulnerability in terms of medications, their exposures, whether they're in San Diego, or via Chicago, or the Cornfields, you know, what is triggering some of their illness, and some of the sinuses. These are all things that are worth the investigation.

Anju Peters, MD: Well, thank you. And thank you everyone for watching this peer exchange. If you enjoyed the content, please subscribe for our E-newsletters to receive upcoming peer exchanges and other great content right in your inbox. Thank you.

Transcript edited for clarity